Trends in Outcome and Cost of Hospitalization in Chronic Inflammatory Demyelinating Polyneuropathy Patients Treated with IVIG, Versus Steroid or Other Treatments (2009-2013). A New York Statewide Planning and Research Cooperation System (SPARCS) Database Report (P2.270)

Objective: Comparing outcomes and costs between CIDP treatment modalities, steroids vs Intravenous Immunoglobulines (IVIG), vs other treatments Background: IVIg is increasingly used as an alternative treatment to steroids for management of CIDP. Methods: SPARCS in patient database was used to identify CIDP patients between 2009-2013. In-hospital outcomes of CIDP patients treated with IVIG were compared to those treated by steroids or other treatments. Chi-square test for categorical variables and the two-sample t-test or Wilcoxon rank-sum test for continuous variables were used. Results: A total of 1070 patients were analyzed. Patients treated with IVIG are significantly older than those treated with steroids. (median age 66 vs 52 years old p <0.001) There was no significant difference in length of stay between IVIg and steroid groups (p=0.261), nor in average charges $74,600--62,800(p=0.702) between the three groups. There a significantly higher association of the group treated with steroids with diabetes compared to the group treated with IVIG or other modalities (47[percnt] vs 25[percnt] and 28[percnt] p =0.011). Home discharge rates were significantly higher for IVIg patients (52[percnt]) compared to patients treated with steroids. p<0.002. Multiple readmissions were significantly higher in the steroid group compared to the IVIG group. p<0.001. Conclusions: Although we did not observe significant difference in in patient charges and length of hospitalization between CIDP patients treated with IVIG and steroids, we demonstrated a significantly higher discharge to hospice and skilled nursing facility/short term facility as well as more prevalence of diabetes in CIDP patients treated with steroids compared to those treated with IVIG. This may impact the cost of CIDP patients treated with steroids when the out patient cost is taken into consideration. Work in progress to merge SPARKS inpatient and outpatients databases for more global evaluation of the outcome of CIDP patients treated with IVIG and steroids. Disclosure: Dr. El-Ghanem has nothing to disclose. Dr. Gomez has nothing to disclose. Dr. Nasar has nothing to disclose. Dr. Souayah has received personal compensation for activities Grifols as a consultant and/or speakers bureau participant.